drugset / Trial / NCT03905291
Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
To determine the pharmacokinetic/pharmacodynamic characteristics and safety/tolerability of MT921 in Healthy Subjects
Timeline
- Start
- 2018-07-31
- Primary completion
- 2018-12-26
- Completion
- 2018-12-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MT921 | Unknown | 60 mg | — |
| Subject | MT921 | Unknown | 120 mg | — |
| Subject | MT921 | Unknown | 150 mg | — |
Indications
No indication recorded.